Whedy Wang

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
28 papers · 2,498 citations · H-index 13

PAPERS

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
202118 citationsauthor #3
HEMODYNAMIC EFFECTS AND CARDIOVASCULAR SAFETY OF ONCE-DAILY ORAL AMPRELOXETINE (TD-9855), A NOREPINEPHRINE REUPTAKE INHIBITOR, IN HEALTHY ADULTS AND SUBJECTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION
20200 citationsauthor #3
An Open-Label Phase 2 Study to Explore the Durability of Effect, and Safety of Once-Daily Oral Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, for the Symptomatic Treatment of Neurogenic Orthostatic Hypotension in Subjects With Synucleinopathies (866)
20200 citationsauthor #3
Lattice Squares
20204 citationsauthor #2
Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
201716 citationsauthor #3
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates.
20174 citationsauthor #4
Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
20164 citationsauthor #4
Biomarker Evaluation and Subgroup Identification in a Pneumonia Development Program Using SIDES
20157 citationsauthor #5
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
201521 citationsauthor #3
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance
20157 citationsauthor #3
The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
201334 citationsauthor #2
DOSE ADJUSTMENT PRACTICES OF PEGINESATIDE VS. EPOETIN IN EMERALD 1 AND 2 PIVOTAL TRIALS
20121 citationsauthor #2
Anaemia in CKD 5D
20111 citationsauthor #6
Relationship Between Nonsustained Ventricular Tachycardia After Non–ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death: Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN
2010117 citationsauthor #6
Abstract 2562: Number of Consecutive Ectopic Beats of Non-Sustained Ventricular Tachycardia Episode Predicts Sudden Cardiac Death in Patients With Non-ST-Elevation ACS
20090 citationsauthor #1
Abstract 5336: Presence of Ischemia and Non-Sustained Ventricular Tachycardia is Strongly Associated With the Risk of Cardiovascular Outcomes: Observations From the MERLIN-TIMI 36 Trial
20090 citationsauthor #6
Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus.
200959 citationsauthor #6
Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial.
200846 citationsauthor #8
39.21: Heart Rate Response to Adenosine and Regadenoson in Patients with Diabetes: Evidence for Sympathetic Denervation
20072 citationsauthor #5
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial
2007337 citationsauthor #12
Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.
2005241 citationsauthor #13
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
2004670 citationsauthor #7
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
2004552 citationsauthor #8
Ranolazine increases exercise performance and decreases hemoglobin A1C in angina patients with diabetes
20038 citationsauthor #8
Clinical experience with ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, in ischemic heart disease
20010 citationsauthor #3
A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients
2001262 citationsauthor #14
Psychological distress, drug and alcohol use as correlates of condom use in HIV‐serodiscordant heterosexual couples
199389 citationsauthor #7

TIMELINE

1993 89 citations

2001 262 citations

2003 8 citations

2004 1,222 citations

2005 241 citations

2007 339 citations

2008 46 citations

2009 59 citations

2010 117 citations

2011 1 citations

2012 1 citations

2013 34 citations

2015 35 citations

2016 4 citations

2017 20 citations

2020 4 citations

2021 18 citations

Whedy Wang

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT